Lemaitre Vascular Inc Dossier
Qualitative Analysis
Business overview
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a leading global provider of medical devices, implants, and services specialized for the treatment of peripheral vascular disease. Founded in 1983, the company primarily serves vascular surgeons with a highly differentiated, clinician-centric portfolio of disposable and implantable devices used in open vascular surgery. Its core product lines include biologic and synthetic vascular grafts (such as Artegraft), valvulotomes, carotid shunts, and embolectomy catheters. LeMaitre operates a highly successful direct-to-hospital sales model across major global geographies, including the Americas, EMEA, and APAC, which supports its strong pricing power and industry-leading gross margins.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from distributor relationships to a direct-to-hospital sales model in high-value international markets to boost average selling prices (ASPs) and deepen clinical partnerships.
Expected impact: Aims to sustain double-digit organic growth and capture higher margins by selling directly to hospitals in over 25 countries.
Prioritizing proprietary biologic implants (such as Artegraft and XenoSure bovine patches) which represent over 50% of sales, while phasing out lower-margin third-party distribution agreements.
Expected impact: Drives gross margin expansion (targeting over 72%) and secures high-rivalry niche market leadership.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the Artegraft Bovine Carotid Artery Graft to expand LeMaitre's biologic graft offerings and transition the company into a biologics-driven compounder.
Financial impact: Generated significant U.S. sales ($37 million in 2024) and is expanding internationally with a target of $10 million in OUS sales in 2026.
Acquisition of human tissue cryopreservation services to provide cryopreserved human tissue grafts (veins, arteries, and cardiac valved conduits).
Financial impact: Supports high-margin services revenue and serves as a platform for international expansion into Germany and Ireland.